High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

Haematologica. 2014 Feb;99(2):e14-6. doi: 10.3324/haematol.2013.090142.
No abstract available

Keywords: BLIMP1; IRF4; XBP1; bortezomib; multiple myeloma biomarker.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Biomarkers, Tumor / biosynthesis*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • DNA-Binding Proteins / biosynthesis*
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Humans
  • Male
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / metabolism
  • Multiple Myeloma* / mortality
  • Neoplasm Proteins / biosynthesis*
  • Pyrazines / administration & dosage*
  • Regulatory Factor X Transcription Factors
  • Survival Rate
  • Transcription Factors / biosynthesis*
  • X-Box Binding Protein 1

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Boronic Acids
  • DNA-Binding Proteins
  • Neoplasm Proteins
  • Pyrazines
  • Regulatory Factor X Transcription Factors
  • Transcription Factors
  • X-Box Binding Protein 1
  • XBP1 protein, human
  • Bortezomib